<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Atossa Genetics Inc — News on 6ix</title>
<link>https://6ix.com/company/atossa-genetics-inc</link>
<description>Latest news and press releases for Atossa Genetics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/atossa-genetics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835496878dffbe2df0e43e3.webp</url>
<title>Atossa Genetics Inc</title>
<link>https://6ix.com/company/atossa-genetics-inc</link>
</image>
<item>
<title>Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-strengthens-clinical-leadership-team-with-the-addition-of-two-experienced-biopharma-executives</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-strengthens-clinical-leadership-team-with-the-addition-of-two-experienced-biopharma-executives</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement</description>
</item>
<item>
<title>Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-presents-clinical-trial-update-highlighting-z-endoxifen-research-at-the-2026-mda-clinical-and-scientific-conference-8</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-presents-clinical-trial-update-highlighting-z-endoxifen-research-at-the-2026-mda-clinical-and-scientific-conference-8</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic MiceSEATTLE, March 12, 2026</description>
</item>
<item>
<title>Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-issues-letter-shareholders-133000256</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-issues-letter-shareholders-133000256</guid>
<pubDate>Wed, 11 Feb 2026 13:30:00 GMT</pubDate>
<description>Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</description>
</item>
<item>
<title>Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-maintains-strong-market-133000417</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-maintains-strong-market-133000417</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today reaffirmed its strong market position around its Duchenne Muscular Dystrophy (DMD) program following yesterday's congressional announcement that it had passed a five-year reauthorization of the Rare Pediatric Disease Priority Review Voucher ("PRV") Program. The program extends the Company's abili</description>
</item>
<item>
<title>Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-founder-ceo-steven-140500087</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-founder-ceo-steven-140500087</guid>
<pubDate>Wed, 21 Jan 2026 14:05:00 GMT</pubDate>
<description>Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, announces that Founder, Chairman, President, and Chief Executive Officer Steven Quay, M.D., Ph.D. has been selected as one of "The Top 50 Healthcare Technology CEOs of 2025" by The Healthcare Technology Report.</description>
</item>
<item>
<title>Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy</guid>
<pubDate>Fri, 16 Jan 2026 05:00:00 GMT</pubDate>
<description>Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease</description>
</item>
<item>
<title>Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-receives-fda-study-may-proceed-letter-for-z-endoxifen-investigational-new-drug-application-for-metastatic-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-receives-fda-study-may-proceed-letter-for-z-endoxifen-investigational-new-drug-application-for-metastatic-breast-cancer</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for</description>
</item>
<item>
<title>Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-wins-2025-clinical-trials-arena-research-and-development-excellence-award-in-precision-endocrine-therapy-category</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-wins-2025-clinical-trials-arena-research-and-development-excellence-award-in-precision-endocrine-therapy-category</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease</description>
</item>
<item>
<title>Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-presents-four-clinical-trial-updates-highlighting-z-endoxifen-research-at-the-2025-san-antonio-breast-cancer-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-presents-four-clinical-trial-updates-highlighting-z-endoxifen-research-at-the-2025-san-antonio-breast-cancer-symposium</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reductionSEATTLE, Dec. 15, 2025</description>
</item>
<item>
<title>Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon</description>
</item>
<item>
<title>Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-announces-issuance-of-us-patent-covering-enteric-oral-z-endoxifen-formulations-and-methods-of-treating-patients-using-z-endoxifen</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-announces-issuance-of-us-patent-covering-enteric-oral-z-endoxifen-formulations-and-methods-of-treating-patients-using-z-endoxifen</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven</description>
</item>
<item>
<title>Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-details-accelerated-fda-strategy-to-advance-z-endoxifen-across-breast-cancer-continuum</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-details-accelerated-fda-strategy-to-advance-z-endoxifen-across-breast-cancer-continuum</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settingsSEATTLE, Dec. 4, 2025 /PRNewswire/ -- Atossa</description>
</item>
<item>
<title>Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/insilico-medicine-and-atossa-therapeutics-publish-ai-driven-study-in-nature-scientific-reports-identifying-z-endoxifen-as-a-potential-therapeutic-candidate-for-glioblastoma</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/insilico-medicine-and-atossa-therapeutics-publish-ai-driven-study-in-nature-scientific-reports-identifying-z-endoxifen-as-a-potential-therapeutic-candidate-for-glioblastoma</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics</description>
</item>
<item>
<title>Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-highlights-emerging-opportunity-for-z-endoxifen-in-duchenne-muscular-dystrophy-including-symptomatic-female-carriers-following-peer-reviewed-publication-and-scientific-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-highlights-emerging-opportunity-for-z-endoxifen-in-duchenne-muscular-dystrophy-including-symptomatic-female-carriers-following-peer-reviewed-publication-and-scientific-presentation</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>Published article outlines rationale for multi-pathway efficacy for (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD); November scientific presentation to</description>
</item>
<item>
<title>Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling</description>
</item>
<item>
<title>Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-announces-acceptance-of-four-abstracts-highlighting-z-endoxifen-research-for-presentation-at-the-2025-san-antonio-breast-cancer-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-announces-acceptance-of-four-abstracts-highlighting-z-endoxifen-research-for-presentation-at-the-2025-san-antonio-breast-cancer-symposium</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention SEATTLE, Nov. 6, 2025 /PRNewswire/ -- Atossa</description>
</item>
<item>
<title>Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-highlights-progress-in-recasttm-dcis-platform-trial-at-early-detection-research-conference-laura-esserman-md-mba-to-discuss-active-surveillance-strategy-and-novel-endocrine-agents</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-highlights-progress-in-recasttm-dcis-platform-trial-at-early-detection-research-conference-laura-esserman-md-mba-to-discuss-active-surveillance-strategy-and-novel-endocrine-agents</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk development of (Z)-Endoxifen and</description>
</item>
<item>
<title>Atossa Therapeutics to Present at the Maxim Growth Summit 2025</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-to-present-at-the-maxim-growth-summit-2025</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-therapeutics-to-present-at-the-maxim-growth-summit-2025</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Invites New Investors to Learn More About $ATOS SEATTLE, Oct. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"),</description>
</item>
<item>
<title>Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness</title>
<link>https://6ix.com/company/atossa-genetics-inc/news/atossa-appoints-mark-daniel-cpa-as-chief-financial-officer-to-lead-finance-systems-and-capital-strategy-for-commercial-readiness</link>
<guid isPermaLink="true">https://6ix.com/company/atossa-genetics-inc/news/atossa-appoints-mark-daniel-cpa-as-chief-financial-officer-to-lead-finance-systems-and-capital-strategy-for-commercial-readiness</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for</description>
</item>
</channel>
</rss>